Press releaseBusiness Wire
Estrella Immunopharma
ESLAW · NASDAQ
$0.0799+$0.0117 (+17.16%)TodayMarket closed ·
Prev close $0.0682
Latest news
- Press releaseBusiness Wire
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
- Press releaseBusiness Wire
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
- Press releaseBusiness Wire
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
- Press releaseBusiness Wire
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
- Press releaseBusiness Wire
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
- Press releaseBusiness Wire
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
- Press releaseBusiness Wire
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
- Press releaseBusiness Wire
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.